About Us
Xention is a Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs. The Company has potential breakthrough drugs for atrial fibrillation overactive bladder in clinical development as well as preclinical research programmes focused on other ion channel targets in atrial fibrillation and autoimmune disease.
Ion channels are widely recognised as a highly specialised and underexploited class of drug target, and Xention has overcome many of the difficulties associated with these targets through its proprietary discovery approach that allows the company to design and optimise potent and selective small-molecule drugs.
Using its expertise in both discovery and clinical development, Xention aims to develop a portfolio of products that will address areas of substantial unmet medical need in rapidly evolving fields of medicine.
- Our goal is to create innovative new medicines that improve patient outcomes
- Our expertise is the research and development of safe and effective medicines that regulate ion channels and modulate disease processes
- We seek to develop proprietary products for the treatment of cardiovascular disease and urinary tract disorders
- Our intent is to create, build and realise returns to shareholders over the medium term